Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29080900 | 0.86 | SLC40A1 (0.46) | SLC40A1HDAC1HDAC6ARG1RIPK1 | |
| SCHEMBL30587462 | 0.84 | SLC40A1 (0.41) | SLC40A1HDAC1HDAC6RIPK1HDAC4 | |
| SCHEMBL18367255 | 0.84 | SLC40A1 (0.41) | SLC40A1HDAC1HDAC6RIPK1HDAC4 | |
| SCHEMBL18367260 | 0.83 | SLC40A1 (0.42) | SLC40A1HDAC1HDAC6RIPK1HSD17B13 | |
| SCHEMBL18367234 | 0.83 | EGLN1 (0.40) | RIPK1KLKB1 | |
| SCHEMBL22736834 | 0.81 | CA5A (0.46) | HDAC1HDAC6RIPK1HDAC4HDAC2 | |
| SCHEMBL18366876 | 0.80 | RIPK1 (0.50) | HDAC1HDAC6RIPK1HDAC4HDAC2 | |
| SCHEMBL30434549 | 0.80 | RIPK1 (0.50) | HDAC1HDAC6RIPK1HDAC4HDAC2 | |
| SCHEMBL18366890 | 0.78 | RIPK1 (0.42) | HDAC1HDAC6RIPK1HDAC4HDAC2 | |
| SCHEMBL30035923 | 0.78 | RIPK1 (0.42) | HDAC1HDAC6RIPK1HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023119210-A1 | NOVEL COMPOUND AS RIPK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | SLC40A1 3554/4885HDAC1 256/4885HDAC6 786/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | SLC40A1 3554/4885HDAC1 256/4885HDAC6 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.